Research programme: estrogen receptor ligands - ENDECE

Drug Profile

Research programme: estrogen receptor ligands - ENDECE

Alternative Names: NDC 1022; NDC 1308; NDC 1352; NDC 1407

Latest Information Update: 21 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ENDECE
  • Class Estradiol congeners; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cell differentiation stimulants; Estrogen receptor agonists; Estrogen receptor alpha agonists; Estrogen receptor beta agonists; Estrogen receptor modulators; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Preclinical Alzheimer's disease; Multiple sclerosis
  • Research Neuropathic pain
  • No development reported Cancer; Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (IV)
  • 12 Jul 2016 ENDECE has patent protection for NDC 1308 in USA, Europe, Canada, Australia, China and Singapore
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top